A Prospective Study of Patients With Hypoplastic Left Heart Syndrome (HLHS) Following Stage II Surgical Palliation
Status: | Recruiting |
---|---|
Conditions: | Cardiology |
Therapuetic Areas: | Cardiology / Vascular Diseases |
Healthy: | No |
Age Range: | Any |
Updated: | 4/5/2019 |
Start Date: | October 2012 |
End Date: | November 2020 |
Contact: | Karen S Miller |
Email: | miller.karen1@mayo.edu |
Phone: | 507-266-5510 |
Hypoplastic left heart syndrome (HLHS) is a severe form of congenital heart disease that
consists of multiple obstructions to flow through the left heart and aorta, as well as
hypoplasia of the left ventricle. Most patients require a three-stage surgical protocol
starting within days of birth. Stage I of this process is the Norwood reconstruction (within
the first few days of life), Stage II (usually required within 3-8 months) involves creation
of a direct connection between the patient's superior vena cava and the pulmonary arterial
confluence (bidirectional Glenn anastomosis), and the last stage is creation of a Fontan
circulation (typically within the first 2-4 years). This "single ventricle" approach requires
the right ventricle to perform as the only circulatory pump for the entire body.
Our long-term goal is to develop regenerative strategies to strengthen and augment the right
ventricular muscle of the single-ventricle heart following surgical palliation in HLHS
patients. To determine the safety and feasibility of a cell-based therapeutic intervention at
the Stage II surgery, we aim to document the natural history of post-surgical care in HLHS
patients having undergone standard of care with protocol specific follow-up over the course
of a 6-month period.
This prospective study will document the natural history in patients with HLHS after planned
Stage II surgical palliation with a focus on cardiovascular parameters within 6 months
following surgery in 10 patients.
consists of multiple obstructions to flow through the left heart and aorta, as well as
hypoplasia of the left ventricle. Most patients require a three-stage surgical protocol
starting within days of birth. Stage I of this process is the Norwood reconstruction (within
the first few days of life), Stage II (usually required within 3-8 months) involves creation
of a direct connection between the patient's superior vena cava and the pulmonary arterial
confluence (bidirectional Glenn anastomosis), and the last stage is creation of a Fontan
circulation (typically within the first 2-4 years). This "single ventricle" approach requires
the right ventricle to perform as the only circulatory pump for the entire body.
Our long-term goal is to develop regenerative strategies to strengthen and augment the right
ventricular muscle of the single-ventricle heart following surgical palliation in HLHS
patients. To determine the safety and feasibility of a cell-based therapeutic intervention at
the Stage II surgery, we aim to document the natural history of post-surgical care in HLHS
patients having undergone standard of care with protocol specific follow-up over the course
of a 6-month period.
This prospective study will document the natural history in patients with HLHS after planned
Stage II surgical palliation with a focus on cardiovascular parameters within 6 months
following surgery in 10 patients.
Inclusion Criteria:
- Individuals with HLHS having undergone Stage I surgical palliation and undergoing
planned Stage II palliative Glenn surgery.
- Individuals up to 18 months of age are eligible if written informed consent can be
obtained from both parents and/or legal guardians, unless one parent is not reasonably
available.
Exclusion Criteria:
- Severe chronic diseases, extensive extra-cardiac syndromic features, or history of
cancer
The following complications of congenital heart disease:
- Any condition requiring urgent, or unplanned procedure within 15 days prior to Stage
II surgical repair.
- Severe pulmonary hypertension (reported in the medical record as >70% systemic
pressure).
- Other clinical concerns as documented by a site investigator that would predict (more
likely to happen than not to happen) a risk of severe complications or very poor
outcome during or after Stage II surgical repair.
We found this trial at
3
sites
Rochester, Minnesota 55905
Principal Investigator: Muhammad Y Qureshi, MBBS
Phone: 507-266-5510
Click here to add this to my saved trials
South 34th Street
Philadelphia, Pennsylvania 19104
Philadelphia, Pennsylvania 19104
215-590-1000
Principal Investigator: Joseph W. Rossano, M.D.
Phone: 267-425-6614
Children's Hospital of Philadelphia Since its start in 1855 as the nation's first hospital devoted...
Click here to add this to my saved trials
Oklahoma City, Oklahoma 73104
Principal Investigator: Harold M Burkhart, M.D.
Phone: 405-271-8001
Click here to add this to my saved trials